Sulforaphane Prevents Hepatic Insulin Resistance by Blocking Serine Palmitoyltransferase 3-Mediated Ceramide Biosynthesis

Nutrients. 2019 May 27;11(5):1185. doi: 10.3390/nu11051185.

Abstract

Sulforaphane (SFA), a naturally active isothiocyanate compound from cruciferous vegetables used in clinical trials for cancer treatment, was found to possess potency to alleviate insulin resistance. But its underlying molecular mechanisms are still incompletely understood. In this study, we assessed whether SFA could improve insulin sensitivity and glucose homeostasis both in vitro and in vivo by regulating ceramide production. The effects of SFA on glucose metabolism and expression levels of key proteins in the hepatic insulin signaling pathway were evaluated in insulin-resistant human hepatic carcinoma HepG2 cells. The results showed that SFA dose-dependently increased glucose uptake and intracellular glycogen content by regulating the insulin receptor substrate 1 (IRS-1)/protein kinase B (Akt) signaling pathway in insulin-resistant HepG2 cells. SFA also reduced ceramide contents and downregulated transcription of ceramide-related genes. In addition, knockdown of serine palmitoyltransferase 3 (SPTLC3) in HepG2 cells prevented ceramide accumulation and alleviated insulin resistance. Moreover, SFA treatment improved glucose tolerance and insulin sensitivity, inhibited SPTLC3 expression and hepatic ceramide production and reduced hepatic triglyceride content in vivo. We conclude that SFA recovers glucose homeostasis and improves insulin sensitivity by blocking ceramide biosynthesis through modulating SPTLC3, indicating that SFA may be a potential candidate for prevention and amelioration of hepatic insulin resistance via a ceramide-dependent mechanism.

Keywords: ceramide; glucose uptake; insulin resistance; liver; sulforaphane.

MeSH terms

  • Animals
  • Ceramides / biosynthesis*
  • Enzyme Inhibitors / pharmacology*
  • Glucose / metabolism*
  • Glycogen / metabolism
  • Hep G2 Cells
  • Hepatocytes / drug effects*
  • Hepatocytes / enzymology
  • Humans
  • Insulin / pharmacology
  • Insulin Receptor Substrate Proteins / metabolism
  • Insulin Resistance*
  • Isothiocyanates / pharmacology*
  • Liver / drug effects*
  • Liver / enzymology
  • Male
  • Mice, Inbred C57BL
  • Palmitic Acid / pharmacology
  • Proto-Oncogene Proteins c-akt / metabolism
  • Serine C-Palmitoyltransferase / antagonists & inhibitors*
  • Serine C-Palmitoyltransferase / genetics
  • Serine C-Palmitoyltransferase / metabolism
  • Signal Transduction
  • Triglycerides / metabolism

Substances

  • Ceramides
  • Enzyme Inhibitors
  • IRS1 protein, human
  • Insulin
  • Insulin Receptor Substrate Proteins
  • Isothiocyanates
  • Triglycerides
  • Palmitic Acid
  • Glycogen
  • SPTLC3 protein, human
  • SPTLC3 protein, mouse
  • Serine C-Palmitoyltransferase
  • Proto-Oncogene Proteins c-akt
  • sulforaphane
  • Glucose